OXY Occidental Petroleum Stock Outlook 2026: After Selling OxyChem to Berkshire, What's Left?

On January 2, 2026, Occidental Petroleum did something unusual: it sold one of its three core businesses to the company that is also its largest shareholder. Berkshire Hathaway paid $9.7 billion cash to acquire OxyChem — OXY’s chemical division — and the deal closed on New Year’s Day. OXY used the proceeds to pay down CrownRock acquisition debt.

Think about the structure that creates. Berkshire Hathaway now holds approximately 26.6% of OXY’s common shares, warrants to buy more at $59.624 per share, OXY preferred stock paying 8%, and — separately — 100% of OxyChem, which used to generate roughly $1–$1.5 billion in annual operating earnings with minimal oil price correlation.

Buffett didn’t just pick OXY as a stock. He bought the most defensible piece of it outright. The remaining OXY is now a more concentrated bet: Permian Basin E&P with premier CrownRock acreage, a modest midstream operation, and the world’s largest direct air capture facility at STRATOS. Less diversified. More leveraged to crude oil.

That’s the story in 2026. Whether it’s attractive depends on where you think oil prices are headed.

The Numbers: What FY2025 Actually Shows

Before getting to strategy, a warning about the metrics you’ll see on most financial data sites.

FY2025 (fiscal year ending December 2025) results, source: stockanalysis.com, May 2026:

Metric	Value
Revenue	$22.075 billion
Operating Income	$4.131 billion
Net Income (GAAP)	$1.647 billion
Diluted EPS	$1.61
Annual Dividend Per Share	$1.04

The TTM figures that most screeners display show net income around $4.056 billion and EPS around $3.97. Do not use these for valuation. Approximately $3.385 billion of that TTM net income is classified as “earnings from discontinued operations” — the gain from the OxyChem sale. It’s a real cash event (the $9.7B sale price was received), but it tells you nothing about OXY’s ongoing earnings power.

The resulting trailing P/E of ~77x is completely uninformative. An investor who sees that and concludes OXY is expensively priced is working from a distorted picture. The more honest valuation frameworks are FCF yield (OXY can generate $5–$6B in FCF annually at $70/barrel Brent, implying an 8–10% FCF yield on a ~$57B market cap) and normalized operating earnings.

Stock price as of May 26, 2026: $57.46. Market cap ~$57.2B. 52-week range: $38.80–$67.45 (source: public market data).

Berkshire’s Multi-Layer Position

Berkshire Hathaway’s exposure to Occidental is more complex than most investors realize:

1. OXY common shares: ~264.94 million shares as of March 31, 2026, approximately 26.6% of common shares outstanding
2. OXY warrants: right to purchase additional OXY shares at $59.624/share — at $57.46 the warrants are just out of the money; any sustained move above $59.62 puts them in the money and creates pressure for Berkshire to exercise
3. OXY preferred stock at 8%: the balance has been reduced by partial redemptions; the current outstanding amount should be verified in OXY’s most recent 10-Q rather than quoted from memory, as OXY has been paying it down
4. OxyChem (100% owned outright): the former chemical segment, now fully Berkshire’s

The common share + warrant position means Berkshire’s economic interest is roughly 32.7% including warrants. Whether Buffett ever pursues a full acquisition is speculative — he has said publicly he has no such intent — but the structure would make it operationally straightforward.

For ordinary investors, what matters is simpler: Berkshire’s continuing open-market accumulation at prices in the $38–$67 range represents a sophisticated long-term buyer’s view of intrinsic value. That’s a signal worth factoring in, not following blindly.

The Permian Basin: CrownRock and What OXY Actually Owns

The CrownRock acquisition (closed mid-2024, ~$12 billion) is the single most important thing that happened to OXY’s asset base in the past several years. CrownRock was a private Midland Basin producer with approximately 94,000 net acres and about 170,000 BOE/day of production.

Combined with OXY’s existing position, the Permian portfolio now exceeds 500,000 BOE/day. The Midland Basin portion of this — Wolfcamp-Spraberry stacked pays — represents some of the highest-quality unconventional oil acreage in North America. OXY’s core Midland Basin wells are economic at Brent crude around $40–$45/barrel. At $65–$75, the free cash flow generation is substantial.

The debt load from CrownRock is real and it’s the primary source of OXY’s valuation discount relative to better-capitalized peers like XOM or CVX. Management has been directing excess cash flow and asset sale proceeds (including the OxyChem $9.7B) toward debt reduction. Each quarter’s earnings release includes net debt progress, and that’s the metric analysts are watching most closely.

My read: at WTI below $60 for an extended period, the debt reduction timeline slips and the stock will underperform. At WTI $70 and above, OXY’s FCF generation capability means it can deleverage faster than the market currently prices in, which is where the upside case lives.

STRATOS DAC: The Option That’s Actually Running

Direct air capture is the technology most skeptical investors don’t take seriously yet, and that skepticism may be right in the medium term. But STRATOS is not a prototype — it’s an operating commercial facility.

What it does: Large contactors draw ambient air over a liquid potassium hydroxide solution. The CO2 reacts with the solution, gets extracted and concentrated through a thermal cycle, and is injected into geological storage about a mile underground. The technology comes from Carbon Engineering, which OXY acquired in 2023.

The economics: Two revenue streams.

First, the IRA Section 45Q credit — $180 per tonne of CO2 captured and geologically stored. At 500,000 tonnes of design capacity, that’s $90 million per year in tax credits at full operation. That’s the floor.

Second, voluntary corporate market. Companies with net-zero commitments (over 1,500 globally) need high-quality, durable carbon removal. Early STRATOS offtake agreements include Airbus (400,000 tonnes) and Amazon (250,000 tonnes over 10 years); the per-tonne contract prices are not disclosed, but high-quality permanent DAC removal credits are widely estimated to trade well above the $180 45Q floor. DAC credits command that premium because CO2 stored geologically is permanent — unlike forestry offsets that can burn or be logged. That quality distinction is what separates STRATOS credits from cheaper offset alternatives.

The bear case on STRATOS is real: the process is energy-intensive (currently using natural gas for heat, which offsets some of the captured CO2), current capture costs are high, and DAC credit pricing depends on sustained corporate ESG commitment that could weaken. I’d treat STRATOS as a free call option attached to the Permian E&P business — not a reason to own OXY by itself, but a meaningful source of upside if the carbon credit market develops as proponents believe.

CEO Vicki Hollub: The Track Record Behind the Buffett Endorsement

Buffett has publicly praised Hollub’s management. That’s worth unpacking.

Hollub’s most controversial decision was the 2019 Anadarko acquisition — OXY paid approximately $57 billion (including debt) to outbid Chevron, financing it in part by accepting Berkshire’s $10 billion preferred stock investment. The deal was immediately criticized as overpaid. Carl Icahn accumulated a stake and waged a proxy campaign.

The subsequent years told a different story. Non-core Anadarko assets were divested faster than expected. Permian acreage proved as valuable as argued. The debt load was reduced. Buffett kept buying common shares. The CrownRock acquisition followed the same playbook: identify high-quality Midland Basin acreage, finance the acquisition, integrate, deleverage through operations.

OxyChem’s sale to Berkshire is also a Hollub decision — $9.7 billion for a business that was generating roughly $1–1.5B in annual operating income. At roughly 6–10x EBIT, the sale price was fair to moderately rich. Using the proceeds to reduce CrownRock debt is consistent with the stated capital allocation priority sequence.

Whether you agree with her decisions or not, the execution has been coherent and the Berkshire relationship is both an endorsement and a financing backstop that no other independent E&P can claim.

Bull, Base, and Bear Scenarios

With OxyChem gone, scenario analysis becomes more oil-price-dependent than before:

Bull ($75–$85): WTI averages $80+. Debt reduction reaches management target by late 2026. Variable dividend supplement introduced, accelerating shareholder returns. STRATOS credit sales announcements drive DAC premium re-rating. Berkshire exercises warrants, adding to ownership.

Base ($60–$68): WTI averages $65–$75. Debt reduction on pace but not ahead of schedule. Permian production stable post-CrownRock integration. STRATOS operates at partial capacity with ongoing credit sales. Dividend maintained, modest buybacks.

Bear ($38–$45): WTI falls to $50–$55 on demand concerns, OPEC production increase, or Iran nuclear deal outcome adding supply. Debt reduction stalls. The variable dividend supplement becomes unlikely. STRATOS credit demand weakens with corporate ESG budget cuts. In this scenario, OXY’s drawdown is substantially larger than XOM’s or CVX’s — the leverage cuts both ways.

Scenario	Oil Price	OXY Range
Bull	WTI $80+	$75–$85
Base	WTI $65–75	$60–$68
Bear	WTI $50–55	$38–$45

OXY vs. XOM vs. CVX: Which to Own and When

The choice between these three isn’t just about price — it’s about what kind of oil exposure you want.

	OXY	XOM	CVX
Oil price beta	High	Medium	Medium
Dividend yield	~1.81%	~3.3%	~4.3%
Balance sheet	Leveraged	Strong	Strong
Unique angle	DAC + Berkshire + debt paydown catalyst	Pioneer + Guyana	Tengiz + LNG

If you want a Roth IRA compounder with rising dividends and minimal drama: XOM or CVX. If you want a higher-beta energy position that amplifies oil price moves, has a legitimate carbon capture business attached, and a 26.6% Berkshire backstop: OXY. The two aren’t substitutes — they serve different portfolio roles.

I’d consider OXY sizing based on your oil price conviction. If you think WTI stays above $65 for the next 2–3 years, the deleveraging story makes OXY one of the more interesting risk-adjusted setups in energy. If you’re uncertain on oil prices, XOM’s integration and dividend cushion make more sense.

The Anadarko Backstory: Why OXY Has Debt in the First Place

To understand OXY’s current balance sheet, you need a quick sketch of 2019. Anadarko Petroleum was one of the most coveted independent E&P companies in the US — premier Permian acreage, Gulf of Mexico deepwater, and a massive Mozambique LNG project. Chevron announced an acquisition at roughly $33 billion. Hollub decided OXY couldn’t afford to let that Permian acreage go to a competitor.

OXY launched a counter-bid at approximately $57 billion (including assumed debt). Chevron walked away, taking a $1 billion break-up fee. To finance the bid, Hollub approached Buffett: Berkshire invested $10 billion in OXY preferred stock at 8% plus warrants to purchase ~83.9 million OXY shares at $59.624. This was the origin of Berkshire’s OXY relationship — not a stock screen, but a deal financing that gave Buffett direct insight into management’s thinking.

The deal was immediately controversial. Carl Icahn called it overpriced and waged a proxy campaign. OXY’s stock fell sharply. Then the integration played out: non-core Anadarko assets were divested faster than expected, the Permian acreage proved as valuable as argued, and by 2022 Buffett was buying OXY common shares in the open market — a meaningful signal that he viewed the original thesis as validated.

The CrownRock acquisition followed the same template. Hollub identified high-quality Midland Basin acreage, financed the acquisition, and is now executing the same deleveraging playbook. OxyChem’s sale to Berkshire is part of that playbook: monetize a non-core (for the E&P strategy) asset at a reasonable multiple and apply proceeds to debt.

Understanding this history makes the current OXY balance sheet legible rather than alarming. The debt is intentional, purposeful leverage on high-quality assets — not reckless accumulation.

Permian Well Economics: Why the Acreage Commands a Premium

When OXY describes its Midland Basin acreage as “premier,” that language needs substance. The Wolfcamp-Spraberry stacked pay formations in the Midland Basin offer something that makes operators willing to pay large premiums for acreage: multiple productive bench targets at different depths within the same acre.

A typical OXY well section might have five to seven separate landing zones — Lower Wolfcamp A, B, C, D; Upper and Lower Spraberry — each productive enough to justify a horizontal well. This means OXY can drill 5–7 wells per section over time, rather than 2–3 in lower-quality acreage. The economics of each incremental well benefit from shared surface infrastructure already in place from earlier wells.

OXY’s core Midland Basin wells produce at breakeven economics with Brent crude around $40–$45/barrel. At $65 Brent, the economics are robust. The 30-day initial production rates from CrownRock wells at acquisition were approximately in the 1,000–1,200 BOE/day range — above basin average — which supported the $12 billion purchase price.

The water management piece matters too. Permian oil production generates enormous volumes of produced water. OXY has invested in water recycling infrastructure that uses produced water for completions rather than disposing of it all via injection wells. This reduces both sourcing cost for completion water and disposal fees — a real competitive advantage as water-related costs have grown in the Permian.

The Midstream Connection

OXY’s midstream and marketing segment is often underweighted in investment analysis. The segment transports and processes oil, gas, and CO2 from OXY’s upstream operations and provides incremental revenue from third-party volumes.

More importantly for the DAC thesis: OXY’s extensive CO2 pipeline infrastructure in the Permian Basin is directly relevant to STRATOS. OXY operates over 5,000 miles of CO2 pipeline in the US, primarily used for CO2 enhanced oil recovery (EOR) where CO2 is injected into older oil fields to boost production. This infrastructure is also usable for transporting and injecting captured CO2 from STRATOS into geological storage — reducing capital requirements for STRATOS expansion versus a greenfield company with no existing CO2 infrastructure.

This pipeline network is one of the structural advantages that makes OXY a more credible DAC operator than a startup would be. It’s a real asset that doesn’t show up prominently in most stock analyses.

The Capital Return Roadmap

Management has communicated a sequenced approach to capital returns:

Phase 1 (current): Debt reduction is the dominant use of cash. Base dividend of $1.04 annualized is maintained. Buybacks are minimal. The $9.7 billion OxyChem sale proceeds went almost entirely to debt paydown.

Phase 2 (post-deleveraging target): Once net debt reaches management’s undisclosed target (analyst estimates cluster around $15–$18 billion), OXY plans to shift toward a base plus variable dividend structure. The variable component would be tied to oil prices above a threshold, similar to the structure Devon Energy implemented successfully.

Phase 3 (sustained return): A fully implemented variable framework where shareholders receive enhanced income in high oil price environments while the base dividend provides a floor.

The timeline to Phase 2 depends almost entirely on WTI. At $70–$75, analysts expect management’s debt target could be reached within 12–18 months. At $60, that timeline extends to 24–30 months. At $55 or below, debt reduction effectively stalls.

For investors: the 1.81% current dividend yield understates OXY’s capital return potential. The full picture is the base dividend plus eventual buybacks plus the variable supplement. Investors who buy and hold through the deleveraging phase are positioned to benefit from the capital return acceleration, not just the current dividend.

How Geopolitics Affects OXY

OXY has international E&P assets — primarily in Oman and the UAE — that give it some geopolitical exposure beyond US operations. Middle East assets generally have lower production costs but higher political risk.

In May 2026, reports of progress on Iran nuclear negotiations moved OXY’s stock sharply lower (down over 7% in a single session). The logic: an Iran deal would potentially return several hundred thousand barrels per day of Iranian oil to global markets, lowering crude prices. OXY’s higher oil price beta means it absorbs that concern more than integrated majors.

This geopolitical sensitivity is simply a cost of owning a leveraged E&P. Investors who are uncomfortable with oil price volatility driven by geopolitical headlines should weight XOM or CVX more heavily, or own OXY through XLE exposure that diversifies across the sector.

What to Watch

The OXY thesis tracks on three quarterly metrics. At each earnings release, I’d check:

Net debt progress: CrownRock closed mid-2024 at ~$12B acquisition cost. The $9.7B OxyChem proceeds went toward this debt. How much net debt remains, and is the trajectory steeper than expected? That’s the deleveraging catalyst.

STRATOS operational data: Actual tonnes captured per quarter vs. design capacity. Credit sales volume and pricing. Any new offtake agreements. This is how you verify the commercial DAC thesis.

Permian well performance: Are the CrownRock wells producing at the productivity levels that justified the $12B acquisition price? This is in OXY’s quarterly investor presentations.

If all three are tracking positively in Q2 2026, the current price looks cheap. If debt reduction is disappointing and STRATOS is running below capacity, the stock deserves more patience.

---

OXY’s Dividend History: A Cautionary and Instructive Tale

OXY’s dividend history is worth knowing before making an income assumption. In 2020, when COVID-19 crashed oil prices to near-zero briefly, OXY slashed its quarterly dividend from $0.79 to $0.01 — a 99% cut. It was one of the most dramatic dividend reductions in the energy sector that year.

The cut wasn’t reckless management — it was math. OXY was carrying heavy Anadarko debt and facing negative free cash flow. The dividend had to give. But investors who had owned OXY for income got wiped out on the income side.

The lesson for 2026: OXY is not an income stock. It’s a total return play where oil price leverage and balance sheet improvement drive returns, with a modest 1.81% yield as a secondary component. Investors who need stable, growing income should weight XOM (which maintained and grew its dividend through 2020 as an integrated major) or CVX.

For investors who understand OXY’s income fragility and are buying for capital appreciation and FCF potential, the 2020 history is less relevant — the deleveraging story is fundamentally different from the Anadarko-overhang situation of 2019–2020. But knowing the history prevents unpleasant surprises.

Related Posts

• XOM ExxonMobil Stock Outlook 2026 — Comparison with the largest U.S. oil major
• CVX Chevron Stock Outlook 2026 — Third major integrated oil comparison
• BRKB Berkshire Hathaway Stock Outlook 2026 — Buffett’s portfolio context for the OXY stake
• Tax-Efficient Dividend Investing 2026 — Energy dividend tax planning
• DRIP Dividend Reinvestment Strategy 2026 — Compounding energy dividends over time
• Stock Capital Gains Tax Guide 2026 — Capital gains treatment for energy stocks

Disclaimer: This post is for informational purposes only and does not constitute investment advice. All investment decisions should be made based on your own financial situation and risk tolerance.